News
Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...
Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...
Pharmaceutical Technology on MSN1d
Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...
LoveBScott on MSN1d
PrEP Side Effects: Separating Fact from FictionHIV prevention pills are no different. The good news is PrEP (pre-exposure prophylaxis) is extremely effective and generally ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback